Revolution Medicines is developing the experimental cancer drug RMC-6236, which targets tumors driven by mutations in the RAS gene.[1] In an earlier study of patients with pancreatic tumors, the tumors shrank in about one-quarter of the participants followed for at least five months after treatment.[1] In previously treated patients with the KRAS G12X mutation, the drug achieved a median progression-free duration of 8.1 months.[1] For those with at least three prior treatments, median progression-free progression was 4.2 months.[1] The company plans to proceed with the 300 mg dose into a phase 3 trial in pancreatic cancer, comparing it to standard chemotherapy in previously treated patients, with an expected start in the second half of the year.[1] The phase 1 study enrolled nearly 400 patients with RAS-driven solid tumors and tested nine doses of the drug.[1] RAS mutations are present in approximately 30% of all cancers.[2]